Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis

BACKGROUND: Although direct-acting antivirals (DAA) have revolutionized the treatment of chronic hepatitis C virus (HCV), many state Medicaid programs have limited coverage because of their expense. In 2015, the Centers for Medicare & Medicaid Services (CMS) notified states about the legality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Herink, Megan C, Geddes, Jonah, Vo, Kim, Zaman, Atif, Hartung, Daniel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391280/
https://www.ncbi.nlm.nih.gov/pubmed/34185560
http://dx.doi.org/10.18553/jmcp.2021.27.7.856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391280/
https://www.ncbi.nlm.nih.gov/pubmed/34185560
http://dx.doi.org/10.18553/jmcp.2021.27.7.856

Ejemplares similares